K

Kanvas Biosciences

HealthMicrobiome Therapies📍 United States

Kanvas Biosciences is focused on developing microbiome-based cancer therapies, leveraging a breakthrough imaging platform to map the gut microbiome. The company aims to improve cancer immunotherapy outcomes and address malnutrition-related gut diseases, with its foundational technology emerging from research at Cornell University.

Total raised
$48M
tracked to date
Latest round
Series A
Jun 8, 2026
Known investors
2
led by DCVC

Is this your company?

Claim this profile to get matched with investors who fund Health startups in United States.

Claim this profile →

🏆 Featured in Datapile’s Q2 2026 USA Funding Report

Read the Q2 2026 USA report →
Add this badge to your site
<a href="https://datapile.co/reports/q2-2026-usa-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q2 2026 USA Funding Report</a>

Funding history

  1. 1
    $48MSeries AJun 8, 2026

    Led by DCVC

    Announcement ↗

Founder

H
Hao Shi
Co-founder

Investors in Kanvas Biosciences

Backers from this company's tracked funding rounds.

  • DDCVCLead investorVC firm
  • LLions CapitalVC firm

Kanvas Biosciences in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile